Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab maintenance and extension study in Crohn's disease responders after induction therapy
CTR20190774Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risankizumab in Crohn's disease, sponsored by AbbVie Inc.. Started Mar 2020; status: active.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20190774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190774.